LY 3154207

Drug Profile

LY 3154207

Alternative Names: LY3154207

Latest Information Update: 22 Apr 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 01 Mar 2016 Eli Lilly completes a pharmacodynamics phase trial in Healthy volunteers in USA (PO) (NCT02603861)
  • 17 Nov 2015 Eli Lilly plans a pharmacodynamics phase I trial in Healthy male volunteers in USA (PO) (NCT02603861)
  • 01 Nov 2015 Eli Lilly initiates enrolment in a phase I trial in Healthy volunteers in USA (PO) (NCT02603861)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top